Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus outcome-related factors study in metastatic renal cell carcinoma after VEGF inhibitor failure
2014-002508-26Phase 4Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Survival free from an unfavourable event. Started Jan 2015; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2014-002508-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002508-26.